Colossal Biosciences reportedly in talks to lift new capital at $20B–$30B valuation
When de-extinction startup Colossal Biosciences revealed final 12 months that it was trying to “resurrect” the dire wolf from genetic materials present in fossils, we argued that, regardless of the controversy surrounding the venture, the corporate was constructing worthwhile applied sciences that justify its $10.2 billion valuation. Now, roughly 16 months later, the startup is…